Beneficial effects of a bradykinin antagonist in a model of gram-negative sepsis

P. C. Ridings, C. R. Blocher, B. J. Fisher, A. A. Fowler, H. J. Sugerman, F. A. Moore, S. Z. Trooskin, Richard Mullins, M. Shabot

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Activation of the kallikrein-kinin system in sepsis has long been recognized, but its role, beneficial or pathologic, has not been determined. Recently, however, specific bradykinin (BK) antagonists have become available and we sought to determine the effects of a BK antagonist, NPC17731, in a model of sepsis-induced acute lung injury (ALI). Methods: Anesthetized swine were studied for 5 hours, receiving a 1-hour infusion of saline (Controls) or live Pseudomonas aeruginosa (Septic untreated). Treatment groups received a 5 mg/kg bolus of NPC17731 followed by a 1 mg/kg bolus hourly commencing either just before sepsis (Pretreatment) or 30 minutes following the onset of sepsis (Posttreatment). Results: Septic untreated animals showed a rapid, progressive decline in arterial PaO2 compared to controls, and this was significantly improved in both treatment groups. Bronchoalveolar lavage at 5 hours in both treatment groups also showed significant decreases in neutrophil (PMN) counts and protein content compared to untreated septic animals, indicating decreased PMN migration and alveolar-capillary membrane damage. Both treatment groups also showed reduced PMN sequestration in the lung compared to untreated animals, although PMNs did exhibit significant upregulation of PMN CD18 receptor expression and superoxide generation. Conclusions: These data imply a significant role for BK in the pathogenesis of sepsis-induced ALI. Use of a competitive BK antagonist significantly attenuated the development of ALI without inhibiting PMN activation. BK antagonists may be a useful adjunct in the armamentarium against sepsis- induced ALI.

Original languageEnglish (US)
Pages (from-to)81-89
Number of pages9
JournalJournal of Trauma - Injury, Infection and Critical Care
Volume39
Issue number1
DOIs
StatePublished - 1995
Externally publishedYes

Fingerprint

Sepsis
Acute Lung Injury
Kallikrein-Kinin System
Bradykinin
Bronchoalveolar Lavage
Therapeutics
Superoxides
Pseudomonas aeruginosa
Bradykinin Receptor Antagonists
Neutrophils
Up-Regulation
Swine
Lung
Membranes
Proteins

Keywords

  • Acute lung injury
  • Adult respiratory distress syndrome
  • Bradykinin
  • Sepsis

ASJC Scopus subject areas

  • Surgery

Cite this

Ridings, P. C., Blocher, C. R., Fisher, B. J., Fowler, A. A., Sugerman, H. J., Moore, F. A., ... Shabot, M. (1995). Beneficial effects of a bradykinin antagonist in a model of gram-negative sepsis. Journal of Trauma - Injury, Infection and Critical Care, 39(1), 81-89. https://doi.org/10.1097/00005373-199507000-00011

Beneficial effects of a bradykinin antagonist in a model of gram-negative sepsis. / Ridings, P. C.; Blocher, C. R.; Fisher, B. J.; Fowler, A. A.; Sugerman, H. J.; Moore, F. A.; Trooskin, S. Z.; Mullins, Richard; Shabot, M.

In: Journal of Trauma - Injury, Infection and Critical Care, Vol. 39, No. 1, 1995, p. 81-89.

Research output: Contribution to journalArticle

Ridings, PC, Blocher, CR, Fisher, BJ, Fowler, AA, Sugerman, HJ, Moore, FA, Trooskin, SZ, Mullins, R & Shabot, M 1995, 'Beneficial effects of a bradykinin antagonist in a model of gram-negative sepsis', Journal of Trauma - Injury, Infection and Critical Care, vol. 39, no. 1, pp. 81-89. https://doi.org/10.1097/00005373-199507000-00011
Ridings, P. C. ; Blocher, C. R. ; Fisher, B. J. ; Fowler, A. A. ; Sugerman, H. J. ; Moore, F. A. ; Trooskin, S. Z. ; Mullins, Richard ; Shabot, M. / Beneficial effects of a bradykinin antagonist in a model of gram-negative sepsis. In: Journal of Trauma - Injury, Infection and Critical Care. 1995 ; Vol. 39, No. 1. pp. 81-89.
@article{0fd1dca0bb3e4a3c869a5ca53967a5a1,
title = "Beneficial effects of a bradykinin antagonist in a model of gram-negative sepsis",
abstract = "Activation of the kallikrein-kinin system in sepsis has long been recognized, but its role, beneficial or pathologic, has not been determined. Recently, however, specific bradykinin (BK) antagonists have become available and we sought to determine the effects of a BK antagonist, NPC17731, in a model of sepsis-induced acute lung injury (ALI). Methods: Anesthetized swine were studied for 5 hours, receiving a 1-hour infusion of saline (Controls) or live Pseudomonas aeruginosa (Septic untreated). Treatment groups received a 5 mg/kg bolus of NPC17731 followed by a 1 mg/kg bolus hourly commencing either just before sepsis (Pretreatment) or 30 minutes following the onset of sepsis (Posttreatment). Results: Septic untreated animals showed a rapid, progressive decline in arterial PaO2 compared to controls, and this was significantly improved in both treatment groups. Bronchoalveolar lavage at 5 hours in both treatment groups also showed significant decreases in neutrophil (PMN) counts and protein content compared to untreated septic animals, indicating decreased PMN migration and alveolar-capillary membrane damage. Both treatment groups also showed reduced PMN sequestration in the lung compared to untreated animals, although PMNs did exhibit significant upregulation of PMN CD18 receptor expression and superoxide generation. Conclusions: These data imply a significant role for BK in the pathogenesis of sepsis-induced ALI. Use of a competitive BK antagonist significantly attenuated the development of ALI without inhibiting PMN activation. BK antagonists may be a useful adjunct in the armamentarium against sepsis- induced ALI.",
keywords = "Acute lung injury, Adult respiratory distress syndrome, Bradykinin, Sepsis",
author = "Ridings, {P. C.} and Blocher, {C. R.} and Fisher, {B. J.} and Fowler, {A. A.} and Sugerman, {H. J.} and Moore, {F. A.} and Trooskin, {S. Z.} and Richard Mullins and M. Shabot",
year = "1995",
doi = "10.1097/00005373-199507000-00011",
language = "English (US)",
volume = "39",
pages = "81--89",
journal = "Journal of Trauma and Acute Care Surgery",
issn = "2163-0755",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Beneficial effects of a bradykinin antagonist in a model of gram-negative sepsis

AU - Ridings, P. C.

AU - Blocher, C. R.

AU - Fisher, B. J.

AU - Fowler, A. A.

AU - Sugerman, H. J.

AU - Moore, F. A.

AU - Trooskin, S. Z.

AU - Mullins, Richard

AU - Shabot, M.

PY - 1995

Y1 - 1995

N2 - Activation of the kallikrein-kinin system in sepsis has long been recognized, but its role, beneficial or pathologic, has not been determined. Recently, however, specific bradykinin (BK) antagonists have become available and we sought to determine the effects of a BK antagonist, NPC17731, in a model of sepsis-induced acute lung injury (ALI). Methods: Anesthetized swine were studied for 5 hours, receiving a 1-hour infusion of saline (Controls) or live Pseudomonas aeruginosa (Septic untreated). Treatment groups received a 5 mg/kg bolus of NPC17731 followed by a 1 mg/kg bolus hourly commencing either just before sepsis (Pretreatment) or 30 minutes following the onset of sepsis (Posttreatment). Results: Septic untreated animals showed a rapid, progressive decline in arterial PaO2 compared to controls, and this was significantly improved in both treatment groups. Bronchoalveolar lavage at 5 hours in both treatment groups also showed significant decreases in neutrophil (PMN) counts and protein content compared to untreated septic animals, indicating decreased PMN migration and alveolar-capillary membrane damage. Both treatment groups also showed reduced PMN sequestration in the lung compared to untreated animals, although PMNs did exhibit significant upregulation of PMN CD18 receptor expression and superoxide generation. Conclusions: These data imply a significant role for BK in the pathogenesis of sepsis-induced ALI. Use of a competitive BK antagonist significantly attenuated the development of ALI without inhibiting PMN activation. BK antagonists may be a useful adjunct in the armamentarium against sepsis- induced ALI.

AB - Activation of the kallikrein-kinin system in sepsis has long been recognized, but its role, beneficial or pathologic, has not been determined. Recently, however, specific bradykinin (BK) antagonists have become available and we sought to determine the effects of a BK antagonist, NPC17731, in a model of sepsis-induced acute lung injury (ALI). Methods: Anesthetized swine were studied for 5 hours, receiving a 1-hour infusion of saline (Controls) or live Pseudomonas aeruginosa (Septic untreated). Treatment groups received a 5 mg/kg bolus of NPC17731 followed by a 1 mg/kg bolus hourly commencing either just before sepsis (Pretreatment) or 30 minutes following the onset of sepsis (Posttreatment). Results: Septic untreated animals showed a rapid, progressive decline in arterial PaO2 compared to controls, and this was significantly improved in both treatment groups. Bronchoalveolar lavage at 5 hours in both treatment groups also showed significant decreases in neutrophil (PMN) counts and protein content compared to untreated septic animals, indicating decreased PMN migration and alveolar-capillary membrane damage. Both treatment groups also showed reduced PMN sequestration in the lung compared to untreated animals, although PMNs did exhibit significant upregulation of PMN CD18 receptor expression and superoxide generation. Conclusions: These data imply a significant role for BK in the pathogenesis of sepsis-induced ALI. Use of a competitive BK antagonist significantly attenuated the development of ALI without inhibiting PMN activation. BK antagonists may be a useful adjunct in the armamentarium against sepsis- induced ALI.

KW - Acute lung injury

KW - Adult respiratory distress syndrome

KW - Bradykinin

KW - Sepsis

UR - http://www.scopus.com/inward/record.url?scp=0029100219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029100219&partnerID=8YFLogxK

U2 - 10.1097/00005373-199507000-00011

DO - 10.1097/00005373-199507000-00011

M3 - Article

VL - 39

SP - 81

EP - 89

JO - Journal of Trauma and Acute Care Surgery

JF - Journal of Trauma and Acute Care Surgery

SN - 2163-0755

IS - 1

ER -